Metten Somers

Metten Somers is a psychiatrist and Medical Head of the Affective and Psychotic Disorders Unit of the Department of Psychiatry at the UMC Utrecht. As a result of his work with treatment-resistant depression in combination with an interest in the potential role for psychedelics in psychiatric disorders, Metten became involved as site-PI in the trial ‘Psilocybin in Treatment-Resistant Depression’, the first international large scale multicenter randomized clinical trial investigating the effectiveness and safety of psilocybin in depressive illness, supported by Compass Pathways.

CV

For his Ph.D. thesis, Metten Sommers studied the relationship between language lateralization and left-handedness, using psychiatric genetic and neuroimaging techniques. Several analyses for this research project were performed at the Center for Neurobehavioral Genetics, UCLA, Los Angeles, California, USA, where he worked as a Visiting Researcher.

Before taking his current position, Metten Somers worked as Project Manager for the OPTiMiSE trial, a first episode-psychosis EU FP7 study, that was centrally coordinated from the UMC Utrecht. From 2016-2018 he participated in the Executive MBA program at the Rotterdam School of Management, Erasmus University, Rotterdam, where he graduated with Dean’s Honours.

Media

• Psilocybin in patients with treatment resistant depression: first clinical experiences from a multicenter RCT (ICPR, 2020)